{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:13:08Z","timestamp":1792883588138,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T00:00:00Z","timestamp":1492992000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40263-017-0434-z","type":"journal-article","created":{"date-parts":[[2017,4,23]],"date-time":"2017-04-23T20:41:09Z","timestamp":1492980069000},"page":"495-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["Elucidating the A\u03b242 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer\u2019s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data"],"prefix":"10.1007","volume":"31","author":[{"given":"Petr","family":"Kocis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sinko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Fillit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Hey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,24]]},"reference":[{"key":"434_CR1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MMB, De Strooper B, Frisoni GB, Salloway S, et al. Alzheimer\u2019s disease. Lancet. 2016;388:505\u201317.","journal-title":"Lancet"},{"key":"434_CR2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25\u00a0years. EMBO Mol Med. 2016;8:595\u2013608.","journal-title":"EMBO Mol Med."},{"key":"434_CR3","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"MP Lambert","year":"1998","unstructured":"Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from A\u03b2\u00a01-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci. 1998;95:6448\u201353.","journal-title":"Proc Natl Acad Sci."},{"key":"434_CR4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","volume":"155","author":"L-F Lue","year":"1999","unstructured":"Lue L-F, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer\u2019s disease. Am J Pathol. 1999;155:853\u201362.","journal-title":"Am J Pathol."},{"key":"434_CR5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","volume":"129","author":"KL Viola","year":"2015","unstructured":"Viola KL, Klein WL. Amyloid \u03b2 oligomers in Alzheimer\u2019s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015;129:183\u2013206.","journal-title":"Acta Neuropathol."},{"key":"434_CR6","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1046\/j.1432-1033.2002.03271.x","volume":"269","author":"O Crescenzi","year":"2002","unstructured":"Crescenzi O, Tomaselli S, Guerrini R, Salvadori S, D\u2019Ursi AM, Temussi PA, et al. Solution structure of the Alzheimer amyloid \u03b2-peptide (1-42) in an apolar microenvironment. Eur J Biochem. 2002;269:5642\u20138.","journal-title":"Eur J Biochem."},{"key":"434_CR7","doi-asserted-by":"crossref","first-page":"13365","DOI":"10.1021\/bi0508284","volume":"44","author":"SK Maji","year":"2005","unstructured":"Maji SK, Amsden JJ, Rothschild KJ, Condron MM, Teplow DB. Conformational dynamics of amyloid \u03b2-protein assembly probed using intrinsic fluorescence. Biochemistry. 2005;44:13365\u201376.","journal-title":"Biochemistry."},{"key":"434_CR8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1021\/cn3000247","volume":"3","author":"S Sinha","year":"2012","unstructured":"Sinha S, Lopes DHJ, Bitan G. A key role for lysine residues in amyloid \u03b2-protein folding, assembly, and toxicity. ACS Chem Neurosci. 2012;3:473\u201381.","journal-title":"ACS Chem Neurosci."},{"key":"434_CR9","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0092-8674(93)90635-4","volume":"73","author":"JT Jarrett","year":"1993","unstructured":"Jarrett JT, Lansbury PTJ. Seeding \u201cone-dimensional crystallization\u201d of amyloid: a pathogenic mechanism in Alzheimer\u2019s disease and scrapie? Cell. 1993;73:1055\u20138.","journal-title":"Cell."},{"key":"434_CR10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","volume":"28","author":"F Gervais","year":"2007","unstructured":"Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, et al. Targeting soluble A\u03b2 peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007;28:537\u201347.","journal-title":"Neurobiol Aging."},{"key":"434_CR11","first-page":"1","volume":"3","author":"S Abushakra","year":"2016","unstructured":"Abushakra S, Porsteinsson AP, Vellas B, Cummings J, Gauthier S, Hey JA, et al. Clinical benefits of tramiprosate in Alzheimer\u2019s disease are associated with higher number of APOE4 alleles: the \u201cAPOE4 gene-dose effect\u201d. J Prevent Alzheimers Dis. 2016;3:1\u201310.","journal-title":"J Prevent Alzheimers Dis."},{"key":"434_CR12","doi-asserted-by":"crossref","unstructured":"Bowers KJ, Chow E, Xu H, Dror R, Eastwood MP, Gregersen BA, et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. In: SC conference, proceedings of the ACMIEEE. New York: IEEE; 2006. p. 43\u201356.","DOI":"10.1109\/SC.2006.54"},{"key":"434_CR13","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1021\/ct300203w","volume":"8","author":"D Shivakumar","year":"2012","unstructured":"Shivakumar D, Harder E, Damm W, Friesner RA, Sherman W. Improving the prediction of absolute solvation free energies using the next generation OPLS force field. J Chem Theory Comput. 2012;8:2553\u20138.","journal-title":"J Chem Theory Comput."},{"key":"434_CR14","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/bioinformatics\/btr168","volume":"27","author":"A Bakan","year":"2011","unstructured":"Bakan A, Meireles LM, Bahar I. ProDy: protein dynamics inferred from theory and experiments. Bioinformatics. 2011;27:1575\u20137.","journal-title":"Bioinformatics."},{"key":"434_CR15","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1021\/acs.biochem.5b01259","volume":"55","author":"J Roche","year":"2016","unstructured":"Roche J, Shen Y, Lee JH, Ying J, Bax A. Monomeric A\u03b2 1\u201340and A\u03b2 1\u201342 peptides in solution adopt very similar Ramachandran map distributions that closely resemble random coil. Biochemistry. 2016;55:762\u201375.","journal-title":"Biochemistry."},{"key":"434_CR16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/jmra.1993.1098","volume":"102","author":"V Sklenar","year":"1993","unstructured":"Sklenar V, Piotto M, Leppik R, Saudek V. Gradient-tailored water suppression for 1H-15N HSQC experiments optimized to retain full sensitivity. J Magn Reson A. 1993;102:241\u20135.","journal-title":"J Magn Reson A."},{"key":"434_CR17","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1021\/ja066915g","volume":"129","author":"M Gal","year":"2007","unstructured":"Gal M, Schanda P, Brutscher B, Frydman L. UltraSOFAST HMQC NMR and the repetitive acquisition of 2D protein spectra at Hz rates. J Am Chem Soc. 2007;129:1372\u20137.","journal-title":"J Am Chem Soc."},{"key":"434_CR18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jmb.2006.09.046","volume":"364","author":"Y Yan","year":"2006","unstructured":"Yan Y, Wang C. A\u03b242 is more rigid than A\u03b240 at the C terminus: implications for A\u03b2 aggregation and toxicity. J Mol Biol. 2006;364:853\u201362.","journal-title":"J Mol Biol."},{"key":"434_CR19","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1021\/ja036813f","volume":"126","author":"L Hou","year":"2004","unstructured":"Hou L, Shao H, Zhang Y, Li H, Menon NK, Neuhaus EB, et al. Solution NMR studies of the A\u03b2(1\u221240) and A\u03b2(1\u221242) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J Am Chem Soc. 2004;126:1992\u20132005.","journal-title":"J Am Chem Soc."},{"key":"434_CR20","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1080\/00498250802499459","volume":"38","author":"SG Summerfield","year":"2008","unstructured":"Summerfield SG, Lucas AJ, Porter RA, Jeffrey P, Gunn RN, Read KR, et al. Toward an improved prediction of human in vivo brain penetration. Xenobiotica. 2008;38:1518\u201335.","journal-title":"Xenobiotica."},{"key":"434_CR21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2045-8118-10-12","volume":"10","author":"EC Lange de","year":"2013","unstructured":"de Lange EC. The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects. Fluids Barriers CNS. 2013;10:12.","journal-title":"Fluids Barriers CNS."},{"key":"434_CR22","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1212\/01.wnl.0000244346.08950.64","volume":"67","author":"PS Aisen","year":"2006","unstructured":"Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006;67:1757\u201363.","journal-title":"Neurology."},{"key":"434_CR23","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1021\/ja406831n","volume":"136","author":"LM Young","year":"2014","unstructured":"Young LM, Cao P, Raleigh DP, Ashcroft AE, Radford SE. Ion mobility spectrometry\u2013mass spectrometry defines the oligomeric intermediates in amylin amyloid formation and the mode of action of inhibitors. J Am Chem Soc. 2014;136:660\u201370.","journal-title":"J Am Chem Soc."},{"key":"434_CR24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nchem.2129","volume":"7","author":"LM Young","year":"2015","unstructured":"Young LM, Saunders JC, Mahood RA, Revill CH, Foster RJ, Tu L-H, et al. Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry. Nat Chem. 2015;7:73\u201381.","journal-title":"Nat Chem."},{"key":"434_CR25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1471-4159.2011.07187.x","volume":"117","author":"K Ono","year":"2011","unstructured":"Ono K, Yamada M. Low-n oligomers as therapeutic targets of Alzheimer\u2019s disease. J Neurochem. 2011;117:19\u201328.","journal-title":"J Neurochem."},{"key":"434_CR26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1113\/jphysiol.2005.103754","volume":"572","author":"M Townsend","year":"2006","unstructured":"Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006;572:477\u201392.","journal-title":"J Physiol."},{"key":"434_CR27","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1110\/ps.041292205","volume":"14","author":"ND Lazo","year":"2005","unstructured":"Lazo ND, Grant MA, Condron MC, Rigby AC, Teplow DB. On the nucleation of amyloid \u03b2-protein monomer folding. Protein Sci. 2005;14:1581\u201396.","journal-title":"Protein Sci."},{"key":"434_CR28","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1021\/bi0474867","volume":"44","author":"KL Sciarretta","year":"2005","unstructured":"Sciarretta KL, Gordon DJ, Petkova AT, Tycko R, Meredith SC. A\u03b240-Lactam(D23\/K28) models a conformation highly favorable for nucleation of amyloid. Biochemistry. 2005;44:6003\u201314.","journal-title":"Biochemistry."},{"key":"434_CR29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nsmb.2991","volume":"22","author":"Y Xiao","year":"2015","unstructured":"Xiao Y, Ma B, McElheny D, Parthasarathy S, Long F, Hoshi M, et al. A\u03b2(1\u201342) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer\u2019s disease. Nat Struct Mol Biol. 2015;22:499\u2013505.","journal-title":"Nat Struct Mol Biol."},{"key":"434_CR30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/cbic.200500223","volume":"7","author":"S Tomaselli","year":"2006","unstructured":"Tomaselli S, Esposito V, Vangone P, van Nuland NAJ, Bonvin AMJJ, Guerrini R, et al. The \u03b1-to-\u03b2 conformational transition of Alzheimer\u2019s A\u03b2-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of \u03b2 conformation seeding. Chembiochem. 2006;7:257\u201367.","journal-title":"Chembiochem."},{"key":"434_CR31","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.jasms.2010.05.007","volume":"21","author":"E Martineau","year":"2010","unstructured":"Martineau E, Guzman JM, Rodionova L, Kong X, Mayer PM, Aman AM. Investigation of the noncovalent interactions between anti-amyloid agents and amyloid \u03b2 peptides by ESI-MS. J Am Soc Mass Spectrom. 2010;21:1506\u201314.","journal-title":"J Am Soc Mass Spectrom."},{"key":"434_CR32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/15287398209530146","volume":"9","author":"PJ Soine","year":"1982","unstructured":"Soine PJ, Blanke RV, Guzelian PS, Schwartz CC. Preferential binding of chlordecone to the protein and high density lipoprotein fractions of plasma from humans and other species. J Toxicol Environ Health A. 1982;9:107\u201318.","journal-title":"J Toxicol Environ Health A."},{"key":"434_CR33","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","volume":"13","author":"S Gauthier","year":"2009","unstructured":"Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer\u2019s disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging. 2009;13:550\u20137.","journal-title":"J Nutr Health Aging."},{"key":"434_CR34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403\u201313.","journal-title":"Ann Neurol."},{"key":"434_CR35","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1373\/clinchem.2013.220392","volume":"60","author":"A Leinenbach","year":"2014","unstructured":"Leinenbach A, Pannee J, Dulffer T, Huber A, Bittner T, Andreasson U, et al. Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid in cerebrospinal fluid. Clin Chem. 2014;60:987\u201394.","journal-title":"Clin Chem."},{"issue":"4","key":"434_CR36","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/jnc.13838","volume":"139","author":"J Pannee","year":"2016","unstructured":"Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H, et al. Reference measurement procedure for CSF amyloid beta (A\u03b2)1-42 and the CSF A\u03b21-42\/A\u03b21-40 ratio: a cross-validation study against amyloid PET. J Neurochem. 2016;139(4):651\u20138.","journal-title":"J Neurochem."},{"key":"434_CR37","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1161591","volume":"321","author":"DL Brody","year":"2008","unstructured":"Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, et al. Amyloid dynamics correlate with neurological status in the injured human brain. Science. 2008;321:1221\u20134.","journal-title":"Science."},{"key":"434_CR38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3233\/JAD-142862","volume":"46","author":"S-K Herukka","year":"2015","unstructured":"Herukka S-K, Rummukainen J, Ihalainen J, von Und Zu Fraunberg M, Koivisto AM, Nerg O, et al. Amyloid-beta and tau dynamics in human brain interstitial fluid in patients with suspected normal pressure hydrocephalus. J Alzheimers Dis. 2015;46:261\u20139.","journal-title":"J Alzheimers Dis."},{"key":"434_CR39","doi-asserted-by":"crossref","first-page":"18563","DOI":"10.1073\/pnas.0804758106","volume":"106","author":"K Usui","year":"2009","unstructured":"Usui K, Hulleman JD, Paulsson JF, Siegel SJ, Powers ET, Kelly JW. Site-specific modification of Alzheimer\u2019s peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. Proc Natl Acad Sci. 2009;106:18563\u20138.","journal-title":"Proc Natl Acad Sci."},{"key":"434_CR40","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.1021\/jp801168v","volume":"112","author":"L Triguero","year":"2008","unstructured":"Triguero L, Singh R, Prabhakar R. Comparative molecular dynamics studies of wild-type and oxidized forms of full-length Alzheimer amyloid \u03b2-peptides A\u03b2(1\u221240) and A\u03b2(1\u221242). J Phys Chem B. 2008;112:7123\u201331.","journal-title":"J Phys Chem B."},{"key":"434_CR41","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2013.08.035","volume":"154","author":"J-X Lu","year":"2013","unstructured":"Lu J-X, Qiang W, Yau W-M, Schwieters CD, Meredith SC, Tycko R. Molecular structure of \u03b2-amyloid fibrils in Alzheimer\u2019s disease brain tissue. Cell. 2013;154:1257\u201368.","journal-title":"Cell."},{"key":"434_CR42","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1021\/jacs.6b05129","volume":"138","author":"MT Colvin","year":"2016","unstructured":"Colvin MT, Silvers R, Ni QZ, Can TV, Sergeyev I, Rosay M, et al. Atomic resolution structure of monomorphic A\u03b2 42amyloid fibrils. J Am Chem Soc. 2016;138:9663\u201374.","journal-title":"J Am Chem Soc."},{"key":"434_CR43","doi-asserted-by":"crossref","first-page":"E4976","DOI":"10.1073\/pnas.1600749113","volume":"113","author":"MA W\u00e4lti","year":"2016","unstructured":"W\u00e4lti MA, Ravotti F, Arai H, Glabe CG, Wall JS, B\u00f6ckmann A, et al. Atomic-resolution structure of a disease-relevant A\u03b2(1-42) amyloid fibril. Proc Natl Acad Sci. 2016;113:E4976\u201384.","journal-title":"Proc Natl Acad Sci."},{"key":"434_CR44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.sbi.2003.12.002","volume":"14","author":"R Tycko","year":"2004","unstructured":"Tycko R. Progress towards a molecular-level structural understanding of amyloid fibrils. Curr Opin Struct Biol. 2004;14:96\u2013103.","journal-title":"Curr Opin Struct Biol."},{"key":"434_CR45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.molstruc.2015.03.023","volume":"1094","author":"S Kobayashi","year":"2015","unstructured":"Kobayashi S, Tanaka Y, Kiyono M, Chino M, Chikuma T, Hoshi K, et al. Dependence pH and proposed mechanism for aggregation of Alzheimer\u2019s disease-related amyloid-\u03b2(1-42) protein. J Mol Struct. 2015;1094:109\u201317.","journal-title":"J Mol Struct."},{"key":"434_CR46","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1523\/JNEUROSCI.4650-14.2015","volume":"35","author":"J Burre","year":"2015","unstructured":"Burre J, Sharma M, Sudhof TC. Definition of a molecular pathway mediating alpha-synuclein neurotoxicity. J Neurosci. 2015;35:5221\u201332.","journal-title":"J Neurosci."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-017-0434-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0434-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-017-0434-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T12:01:13Z","timestamp":1496836873000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-017-0434-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,24]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["434"],"URL":"https:\/\/doi.org\/10.1007\/s40263-017-0434-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,24]]}}}